{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-005018","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.521376+00:00","generated_at":"2026-05-26T22:47:19.090341+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aquestive to present Anaphylm data at AAAAI: symptom resolution in 12 min, stable under extreme conditions","bullets":["Median symptom resolution time 12 min vs 74 min without treatment; mean angioedema resolution within 5 min.","Anaphylm matched or exceeded IM epinephrine in all key PK parameters in Phase 2 OASIS study.","Stability and potency maintained under extreme heat, freezing, and water submersion.","Presentations at AAAAI Annual Meeting Feb 28 – Mar 3, 2025 in San Diego."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-005018","json":"https://secwatch.observer/filing/0001628280-25-005018.json","markdown":"https://secwatch.observer/filing/0001628280-25-005018.md","text":"https://secwatch.observer/filing/0001628280-25-005018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025005018/0001628280-25-005018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828025005018/aqst-20250212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:47:19.090341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}